LONDON, UK, 6 th November 2020
Ascension Healthcare is pleased to announce the launch of Flexiseq CBD; the latest addition to the Flexiseq product portfolio.
Flexiseq CBD is specifically aimed at promoting wellness in an everyday, easy to use form and is now available to buy exclusively at leading beauty and health retailer Superdrug , competitively priced at £29.95 (600mg).
Flexiseq CBD’s benefits include:
The high quality of Flexiseq CBD is a result of a carefully curated process. From selecting the soil to sustainable agricultural practices, choice hemp plants, grown in the EU from certified seeds, are meticulously selected for their CBD profile. No artificial fertilisers, pesticides or GM strains are used at any time.
Modern technologies ensure the production of the highest-quality extracts and any impurities are left behind in the plant so that the finished product only contains natural, non-intoxicating phytocannabinoids.
Flexiseq CBD’s new ambassador Alice Maisetti, an international yoga teacher and mindfulness coach, explains why she believes Ascension Healthcare’s superior product will resonate with the UK public:
“As a yoga instructor, my body is my temple. That means a commitment to using products I know to be safe, natural and organic and, when I speak to my clients, they tell me exactly the same thing. I believe Flexiseq CBD can be part of a holistic approach to looking after your body. There is so much synergy between CBD oil and yoga, both are about helping you to relax, de stress and encouraging your body to release the tension that naturally builds up as a result of the hectic lives we find ourselves living.”
Ascension Healthcare is pleased to be entering the thriving UK CBD market today with Flexiseq CBD. In 2019, a r eport by The Centre For Medicinal Cannabis , the only industry membership body for businesses and investors operating in the cannabis based medicinal product (CBMP) market, reported that:
Against this backdrop, Ascension Healthcare fully welcomes the new regulations being implemented by the Food Standards Authority (FSA) , which state that as of 31 March 2021, CBD manufacturers must submit, and have validated, their novel food authorisation applications.
Commenting on the launch, Biresh Roy, CEO of Ascension Healthcare PLC, said: “We have always taken great pride in being able to offer our customers effective alternatives to drug-based products through our Flexiseq range. We’re pleased that the FSA regulations outline a clear path for proving that standards are compliant and that all CBD products are safe, tested and transparent. Flexiseq CBD comes to market in compliance with those high standards and with the backing of Superdrug, one of the nation’s most reputable and loved beauty and health retailers.”
About Ascension Healthcare
Ascension Healthcare is driven by a determination to make a difference where it really matters – allowing people to live their best possible life.
We use patented technologies to treat people in unconventional ways and pride ourselves on differing from typical biopharma businesses by developing and selling safe, high–quality and robustly tested alternatives to current drug products and therapies.
Alongside Flexiseq CBD, Ascension’s Flexiseq range includes clinically proven, drug-free gels formulated to fight against the pain and stiffness associated with joint wear and tear and osteoarthritis.
For more information, about Ascension:
www.ascension.co.uk/
Find Flexiseq online at the following:
www.flexiseq.com
Twitter: @FLEXISEQ
Facebook: www.facebook.com/flexiseq/
Instagram: FlexiseqUK
Ascension Healthcare plc is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis. The Company has three products in clinical development for the treatment of haemophilia A and also a range of internationally marketed products for osteoarthritis sufferers. For more information please visit: www.ascension.co.uk/
For more information contact
Ascension Healthcare plc
Biresh Roy, Chief Executive Officer
[email protected] / +44 (0)20 7291 5400
Consilium Strategic Communications
(European Media and Investor Enquiries)
Lindsey Neville, Ashley Tapp
Tel: +44 (0)20 3709 5700 / [email protected]